TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00371579
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03644342
Drug: Nirapaib
Approvals — FDA: no, EMA: no, PMDA: no
Description: (see treatment regimen and method of treatment assignment)
Study: NCT01941615
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses for 23 days (period A+B)
Study: NCT02654054
Drug: Placebo for Estradiol/Norethindrone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT02654054
Drug: Estradiol/Norethindrone Acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
Study: NCT00420420
Drug: MK0249
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
Study: NCT00420420
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
Study: NCT02364765
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
Study: NCT01777282
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study: NCT01777282
Drug: Alpha-glucosidase inhibitor
Normalized name: Alpha-glucosidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
Study: NCT01215773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching to HEA 200 mg tablet, oral administration
Study: NCT02201004
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01760889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule a day for 26 weeks
Study: NCT03608163
Drug: Placebo (for Naloxone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water nasal spray
Study: NCT03608163
Drug: Placebo (for Diazoxide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taste matched oral placebo for diazoxide
Study: NCT01845441
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
Study: NCT00170781
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04274933
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet; Oral
Study: NCT01381211
Drug: 90Y-RE
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
Study: NCT02573597
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous or bolus administration
Study: NCT01235754
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily transdermal placebo gel
Study: NCT04753008
Drug: Dopamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
Study: NCT01052480
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
Study: NCT01992172
Drug: Photocil for Atopic Dermatitis
Normalized name: Atopica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocil for Atopic Dermatitis
Study: NCT02281799
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa.
Study: NCT04819581
Drug: SP-103
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine topical system 5.4%
Study: NCT01587274
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg twice/ day x 10 days
Study: NCT04300881
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following intravitreal ocriplasmin therapy
Study: NCT02372110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
Study: NCT00739882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
Study: NCT04381520
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, patients will maintain their original antihypertensive drugs. The periods of treatment and follow-up will be one year.
Study: NCT00289887
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
Study: NCT00711243
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
Study: NCT00982787
Drug: Botanical extract from Passiflora incarnata
Normalized name: Passiflora incarnata extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period
Study: NCT03511105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
Study: NCT00026988
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01692626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
Study: NCT04115319
Drug: SEP363856
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
Study: NCT00562848
Drug: GSK962040
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
Study: NCT00562848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo.
Study: NCT03642262
Drug: Mucinex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucinex® 600 mg single dose ER bi-layer tablet
Study: NCT02681861
Drug: ASP6294 Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT02681861
Drug: ASP6294 Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT02681861
Drug: Placebo Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT02681861
Drug: Placebo Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT04603872
Drug: CD19/BCMA Targeted CAR T-cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.
Study: NCT04618523
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination treatment
Study: NCT03242408
Drug: LPCN 1021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate
Study: NCT01365819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
Study: NCT03825939
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 0.9% sterile saline
Study: NCT01159808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules, oral administration, single dose
Study: NCT02377271
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment by bosentan or placebo is randomized
Study: NCT01975675
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Study: NCT03639987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03772340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT04423757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
Study: NCT02571491
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
Study: NCT02673736
Drug: PLX73086
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00902772
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: mg, oral dose
Study: NCT00902772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02884050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active placebo
Study: NCT01608750
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/day, oral, 28 days
Study: NCT00289848
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
Study: NCT01352572
Drug: antidepressant non-response
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants administration for 6 weeks under therapeutic dose nonresponders
Study: NCT03941808
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Study: NCT04319471
Drug: Capecitabine/S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Capecitabine/S-1
Study: NCT04319471
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
Study: NCT00086229
Drug: Glucosamine
Normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03426592
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study.
Study: NCT03775525
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antimetabolite
Study: NCT01211834
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
Study: NCT01211834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously over 1 hour infusion every 4weeks
Study: NCT01211834
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate(MTX) and/or 1 DMARDs
Study: NCT02162134
Drug: Inj. Ketorolac 30 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
Study: NCT02162134
Drug: Inj. Zantac 50mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study: NCT04689035
Drug: AVLX-144
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04689035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01387087
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01387087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01195194
Drug: PRE-TRANSPLANT (PRE=before)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL).
Study: NCT02142504
Drug: Placebo (Saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching norovirus bivalent VLP vaccine
Study: NCT02120352
Drug: ABC/3TC Oral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
Study: NCT02120352
Drug: RPV Oral Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
Study: NCT03461185
Drug: Anti-Angiogenic Drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
Study: NCT00971633
Drug: Comparator: Treatment A (Zofran, ondansetron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
Study: NCT00971633
Drug: Comparator: Treatment B (Zofran, ondansetron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single 8 mg tablet of Zofran marketed in the U.K., taken PO
Study: NCT00971633
Drug: Comparator: Treatment C (Zofran, ondansetron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
Study: NCT01754597
Drug: Peptide Natriurétique de type B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide Natriurétique de type B
Study: NCT01918488
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
Study: NCT01654185
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day
Study: NCT03658785
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
Study: NCT03817853
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study: NCT03817853
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
Study: NCT01436513
Drug: Premarin reference tablet (fasted)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin reference tablet, single dose, fasted conditions
Study: NCT01436513
Drug: Premarin new tablet (fasted)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin new tablet, single dose, fasted conditions
Study: NCT01436513
Drug: Premarin reference tablet (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin reference tablet, single dose, fed conditions
Study: NCT01436513
Drug: Premarin new tablet (fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin new tablet, single dose, fed conditions
Study: NCT02281344
Drug: MMV390048 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as a powder to be prepared as a suspension for oral use
Study: NCT02840526
Drug: Sopodorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
Study: NCT02840526
Drug: Fentanyl WZF
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
Study: NCT02840526
Drug: Oxynorm
Normalized name: Oxynorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mgml-1 concentration oxycodone solution intravenously
Study: NCT02840526
Drug: Paracetamol Kabi
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g paracetamol intravenously every 6 hours
Study: NCT02840526
Drug: Ketonal
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen intravenously every 12 hours
Study: NCT00375960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03068234
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for pirfenidone capsule
Study: NCT03068234
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
Study: NCT01231529
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
Study: NCT03527316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to the other drugs.
Study: NCT03091595
Drug: 15 mg E4/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study: NCT03091595
Drug: 20 mcg EE/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study: NCT02829008
Drug: Treatment of physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
Study: NCT00519857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet p.o, once daily for 3 years
Study: NCT01766076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMC collected for immune activation assays using flowcytometry
Study: NCT01445782
Drug: AZD2115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, oral inhalation (nebuliser solution)
Study: NCT01445782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose, oral inhalation (nebuliser solution)
Study: NCT00893880
Drug: 1% gaseous Nitric Oxide blended in Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
Study: NCT02773147
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00396682
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 - 250 - 350 mg
Study: NCT01455415
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo 3 time a day
Study: NCT00149383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01294774
Drug: KRP203 - 1.2mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762710
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Study: NCT03308890
Drug: 0.5mg Baraclude(entecavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
Study: NCT03308890
Drug: 0.5mg Baraclude(entecavir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
Study: NCT00634036
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo (inert tablet)
Study: NCT03514732
Drug: MELATONIN (MELATL07959)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Capsule Route of administration: Oral